Mineralocorticoid Receptor Antagonism by Finerenone Attenuates Established Pulmonary Hypertension in Rats.

Ly TuRaphaël ThuilletJulie PerrotMina OttavianiEmy Ponsardin Peter Kolkhof Marc Humbert Say Viengchareun Marc Lombès Christophe Guignabert

Published in: Hypertension (Dallas, Tex. : 1979) (2022)

Finerenone treatment appears to be a potential therapy for PAH worthy of investigation and evaluation for clinical use in conjunction with current PAH treatments.

Keyphrases

pulmonary hypertension
polycyclic aromatic hydrocarbons
pulmonary artery
pulmonary arterial hypertension
human health
coronary artery
replacement therapy